WINT Quote, Financials, Valuation and Earnings

Curis, Inc. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of -243.36%. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat Curis, Inc.'s return on equity of -461.34%.

Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 39900%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1259.22%. Given that Windtree Therapeutics, Inc. has higher upside potential than Curis, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Curis, Inc..

Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.

Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Windtree Therapeutics, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus 0.98x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Enzon Pharmaceuticals, Inc. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of --. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat Enzon Pharmaceuticals, Inc.'s return on equity of -5.37%.

Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 39900%. On the other hand Enzon Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Windtree Therapeutics, Inc. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Enzon Pharmaceuticals, Inc..

Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison Enzon Pharmaceuticals, Inc. has a beta of 0.196, suggesting its less volatile than the S&P 500 by 80.447%.

Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enzon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. Enzon Pharmaceuticals, Inc. pays out -163.88% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Windtree Therapeutics, Inc. quarterly revenues are --, which are smaller than Enzon Pharmaceuticals, Inc. quarterly revenues of --. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than Enzon Pharmaceuticals, Inc.'s net income of -$824K. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while Enzon Pharmaceuticals, Inc.'s PE ratio is 96.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus 225.50x for Enzon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LadRx Corp. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of --. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat LadRx Corp.'s return on equity of --.

Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 39900%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Windtree Therapeutics, Inc., analysts believe LadRx Corp. is more attractive than Windtree Therapeutics, Inc..

Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.

Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Windtree Therapeutics, Inc. quarterly revenues are --, which are larger than LadRx Corp. quarterly revenues of --. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of -316.61%. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat Plus Therapeutics, Inc.'s return on equity of --.

Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 39900%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2016.2%. Given that Windtree Therapeutics, Inc. has higher upside potential than Plus Therapeutics, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Plus Therapeutics, Inc..

Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Windtree Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus 4.17x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.